Managing the adverse effects of nonsteroidal anti-inflammatory drugs

Expert Review of Clinical Pharmacology

Volumn 4, Issue 5, 2011, Pages 605-621

  Patrignani, Paola ^a   Tacconelli, Stefania ^a   Bruno, Annalisa ^a   Sostres, Carlos ^b   Lanas, Angel ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

cardiovascular hazard; gastrointestinal toxicity; nonsteroidal anti inflammatory drugs; prostanoids

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; EPIDERMAL GROWTH FACTOR; ESOMEPRAZOLE; ETORICOXIB; FAMOTIDINE; IBUPROFEN; KETOROLAC; LANSOPRAZOLE; LUMIRACOXIB; MISOPROSTOL; NAPROXCINOD; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PIROXICAM; PROSTANOID; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; UNINDEXED DRUG; VALDECOXIB; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ANEMIA; ATHEROTHROMBOSIS; CAPSULE ENDOSCOPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DEATH; CELL DIVISION; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; DEATH; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DIVERTICULOSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INHIBITION; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; ENZYME ACTIVITY; ERADICATION THERAPY; FOLLOW UP; GASTRODUODENAL ULCER; GASTROINTESTINAL COMPLICATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL TOXICITY; GENE DELETION; GENE EXPRESSION; HEART INFARCTION; HEART PROTECTION; HELICOBACTER INFECTION; HOMEOSTASIS; HUMAN; HYPERTENSION; INTESTINE MUCOSA PERMEABILITY; INTESTINE ULCER; LIVER TOXICITY; LOW DRUG DOSE; MALABSORPTION; META ANALYSIS (TOPIC); MITOCHONDRIAL RESPIRATION; MONOTHERAPY; NEONATAL MYOCARDIAL INFARCTION; NEUTROPHIL; NONHUMAN; OCCULT BLOOD; OSTEOARTHRITIS; PAIN; PATHOGENESIS; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PETECHIA; PH; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN DEPLETION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; SMALL INTESTINE DAMAGE; STOMACH DISEASE; STOMACH ULCER; STROKE; THERAPY EFFECT; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; ULCER HEALING; UPPER GASTROINTESTINAL BLEEDING; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; DRUG TOXICITY; GASTROINTESTINAL DISEASES; HUMANS; OSTEOARTHRITIS; RISK FACTORS;

EID: 80052784496     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.36     Document Type: Review

References (168)

1. Burke A, Smyth E, FitzGerald GA. Analgesic-antipyretic agents: pharmacotherapy of gout. In: Goodman & Gilman's the pharmacological basis of therapeutics (11th Edition).Brunton LL, Lazo JS, Parker KL (Eds).McGraw-Hill, NY, USA 673-715 (2006).
2. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345, 433-442 (2001).
3. Massó González EL, Patrignani P, Tacconelli S, Rodríguez LA. Variability of risk of upper gastrointestinal bleeding among nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 62, 1592-1601 (2010).
4. García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol. 52, 1628-1636 (2008).
5. Bueno H, Bardají A, Patrignani P, Martín-Merino E, García-Rodríguez LA. Spanish case-control study to assess NSAID-associated ACS risk investigators. Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome. Am. J. Cardiol. 105, 1102-1106 (2010).
6. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294(5548), 1871-1875 (2001). (Pubitemid 33101574)
7. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J. Lipid Res. 50, S423-S428 (2009).
8. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J. Lipid Res. 50, S237-S242 (2009).
9. Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. J. Lipid Res. 50, S29-S34 (2009).
10. Kulmacz RJ, van der Donk WA, Tsai AL. Comparison of the properties of prostaglandin H synthase-1 and -2. Prog. Lipid Res. 42(5), 377-404 (2003). (Pubitemid 36694104)
11. Harper KA, Tyson-Capper AJ. Complexity of COX-2 gene regulation. Biochem. Soc. Trans. 36, 543-545 (2008). (Pubitemid 351839376)
12. Young LE, Sanduja S, Bemis-Standoli K, Pena EA, Price RL, Dixon DA. The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology 136(5), 1669-1679 (2009).
13. Simmons L, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56, 387-437 (2004). (Pubitemid 39096597)
14. Patrono C, Patrignani P, García Rodríguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J. Clin. Invest. 108(1), 7-13 (2001). (Pubitemid 32634915)
15. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 82(1-4), 85-94 (2007). (Pubitemid 44895440)
16. Bjordal JM, Ljunggren AE, Klovning A, Slørdal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 329(7478), 1317 (2004).
17. Luqmani R, Hennell S, Estrach C et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years).Rheumatology 45, 1167-1169 (2006). (Pubitemid 44542111)
18. Patrignani P, Panara MR, Greco A et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther. 271, 1705-1721 (1994).
19. Patrono C, Ciabattoni G, Pinca E et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb. Res. 17, 317-327 (1980). (Pubitemid 10129020)
20. Patrignani P, Tacconelli S, Capone ML. Risk management profile of etoricoxib: an example of personalized medicine. Ther. Clin. Risk Manag. 4(5), 983-997 (2008).
21. Wallace JL, Chin BC. Inflammatory mediators in gastrointestinal defense and injury. Proc. Soc. Exp. Biol. Med. 214(3), 192-203 (1997).
22. Silen W, Ito S. Mechanisms for rapid re-epithelialization of the gastric mucosal surface. Annu. Rev. Physiol. 47, 217-229 (1985). (Pubitemid 15142379)
23. Tarnawski A, Szabo IL, Husain SS, Soreghan B. Regeneration of gastric mucosa during ulcer healing is triggered by growth factors and signal transduction pathways. J. Physiol. Paris. 95(1-6), 337-344 (2001). (Pubitemid 33020258)
24. Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc. Natl Acad. Sci. USA 98(11), 6470-6475 (2001). (Pubitemid 32488261)
25. Somasundaram S, Sigthorsson G, Simpson RJ et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment. Pharmacol. Ther. 14(5), 639-650 (2000). (Pubitemid 30240758)
26. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. 2, 879-890 (2003). (Pubitemid 37407794)
27. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343(21), 1520-1528 (2000).
28. Schnitzer TJ, Burmester GR, Mysler E et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) reduction in ulcer complications: randomised controlled trial. Lancet 364, 665-674 (2004). (Pubitemid 39140622)
29. Kargman S, Charleson S, Cartwright M et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111, 445-454 (1996). (Pubitemid 26256734)
30. Shigeta J, Takahashi S, Okabe S. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J. Pharmacol. Exp. Ther. 286, 1383-1390 (1998). (Pubitemid 29135552)
31. Schmassmann A, Zoidl G, Peskar BM et al. Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and -2 knockout mice. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G747-G756 (2006).
32. Mizuno H, Sakamoto C, Matsuda K et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112, 387-397 (1997). (Pubitemid 27078825)
33. Takahashi S, Shigeta J, Inoue H, Tanabe T, Okabe S. Localization ofcyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats. Am. J. Physiol. 275, G1137-G1145 (1998).
34. Tanaka A, Araki H, Komoike Y, Hase S, Takeuchi K. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J. Physiol. Paris 95(1-6), 21-27 (2001). (Pubitemid 33020214)
35. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr. Med. Res. Opin. 23(1), 163-173 (2007). (Pubitemid 46201599)
36. Konturek PC, Kania J, Burnat G, Hahn EG, Konturek SJ. Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract. J. Physiol. Pharmacol. 56(5), 57-73 (2005).
37. Gana TJ, Huhlewych R, Koo J. Focal gastric mucosal blood flow in aspirin-induced ulceration. Ann. Surg. 205(4), 399-403 (1987). (Pubitemid 17059432)
38. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119(3), 706-714 (2000).
39. Wallace JL, Cirino G. The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs. Trends Pharmacol. Sci. 15(11), 405-406 (1994). (Pubitemid 24360505)
40. Asako H, Kubes P, Wallace J, Wolf RE, Granger DN. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology 103(1), 146-152 (1992).
41. Asako H, Kubes P, Wallace J, Gaginella T, Wolf RE, Granger DN. Indomethacin-induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am. J. Physiol. 262(5 Pt 1), G903-G908 (1992).
42. Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am. J. Physiol. 259 (3 Pt 1), G462-G467 (1990). (Pubitemid 20317856)
43. Wallace JL, McKnight W, Miyasaka M et al. Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. Am. J. Physiol. 265 (5 Pt 1), G993-G998 (1993).
44. Wallace JL, Arfors KE, McKnight GW. A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit. Gastroenterology 100(4), 878-883 (1991).
45. Lichtenberger LM. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem. Pharmacol. 61(6), 631-637 (2001). (Pubitemid 32239415)
46. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am. J. Med. 86(4), 449-458 (1989). (Pubitemid 19103913)
47. Wolfe MM, Hocking MP, Maico DG, McGuigan JE. Effects of antibodies to gastric inhibitory peptide on gastric acid secretion and gastrin release in the dog. Gastroenterology 84(5 Pt 1), 81941-81983 (1983).
48. Carson JL, Strom BL, Soper KA, West SL, Morse ML. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch. Intern. Med. 147(1), 85-88 (1987). (Pubitemid 17010766)
49. Minocha A and Greenbaum DS. Pill-esophagitis caused by nonsteroidal 1 Burke A, Smyth E, FitzGerald GA. Analgesic-antipyretic agents: pharmacotherapy of gout. In: Goodman & Gilman's the pharmacological basis of therapeutics (11th Edition).Brunton LL, Lazo JS, Parker KL (Eds).McGraw-Hill, NY, USA 673-715 (2006).
50. Kim SL, Hunter JG, Wo JM, Davis LP, Waring JP. NSAIDs, aspirin, and esophageal strictures: are over-the-counter medications harmful to the esophagus? J. Clin. Gastroenterol. 29(1), 32-34 (1999). (Pubitemid 29288199)
51. Lanas AI, Sousa FL, Ortego J, Esteva F, Blas JM, Soria J, Sáinz R. Aspirin renders the oesophageal mucosa more permeable to acid and pepsin. Eur. J. Gastroenterol. Hepatol. 7(11), 1065-1072 (1995). (Pubitemid 26014462)
52. Lichtenberger LM. The hydrophobic barrier properties of gastrointestinal mucus. Annu. Rev. Physiol. 57, 565-583 (1995).
53. Atherton C, Jones J, McKaig B et al. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study. Clin. Gastroenterol. Hepatol. 2, 113-120 (2004). (Pubitemid 38180464)
54. Twiss IM, Burggraaf J, Schoemaker RC et al. The sugar absorption test in the evaluation of the gastrointestinal intolerant to bisphosphonates: studies with oral pamidronate. Clin. Pharmacol. Ther. 69, 431-437 (2001). (Pubitemid 32554548)
55. Sigthorsson G, Crane R, Simon T et al. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 47, 527-532 (2000).
56. Smecuol E, Bai JC, Sugai E et al. Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs. Gut 49, 650-655 (2001). (Pubitemid 32989201)
57. Day JP, Lanas A, Rustagi P et al. Reversible prolonged skin bleeding time in acute gastrointestinal bleeding presumed due to NSAIDs. J. Clin. Gastroenterol. 22, 96-103 (1996).
58. Smecuol E, Pinto MI, Suarez A et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin. Gastroenterol. Hepatol. 7(5), 524-529 (2009).
59. Goldstein JL, Eisen GM, Lewis B et al. Video capsule endoscopy to prospectively assesses small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin. Gastroenterol. Hepatol. 3(2), 133-141 (2005). (Pubitemid 40220308)
60. Patrono C, Baigent C, Hirsh J and Roth G. American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest 133, 199S-233S (2008).
61. Minuz P, Gaino S, Zuliani V et al. Functional role of p38 mitogen activated protein kinase in platelet activation induced by a thromboxane A2 analogue and by 8-iso-prostaglandin F2a. Thromb. Haemost. 87, 888-898 (2002). (Pubitemid 34516619)
62. Capone ML, Tacconelli S, Rodriguez LG, Patrignani P. NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. Pharmacol. Rep. 62(3), 530-535 (2010).
63. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116, 4-15 (2006). (Pubitemid 43121782)
64. Bresalier RS, Sandler RS, Quan H et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) trial investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352(11), 1092-1102 (2005).
65. Solomon SD, McMurray JJ, Pfeffer MA et al. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352(11), 1071-1080 (2005). (Pubitemid 40365348)
66. Kearney PM, Baigent C, Godwin J et al. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332, 1302-1308 (2006).
67. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342, c7086 (2011).
68. Catella-Lawson F McAdam B, Morrison BW et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289, 735-741 (1999). (Pubitemid 29191226)
69. Stitham J, Arehart EJ, Gleim SR, Douville KL, Hwa J. Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations. Prostaglandins Other Lipid Mediat. 82, 95-108 (2007). (Pubitemid 44880168)
70. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69, 180-186 (1987). (Pubitemid 17007095)
71. Capone ML, Tacconelli S, Sciulli MG et al. Human pharmacology of naproxen sodium. J. Pharmacol. Exp. Ther. 322, 453-460 (2007). (Pubitemid 47105773)
72. Capone ML, Tacconelli S, Sciulli MG et al. Clinical pharmacology of platelet monocyte and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109, 1468-1471 (2004). (Pubitemid 38420172)
73. Singh R, Kumar R, Singh DP. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs: gastrointestinal-sparing potential drugs. J. Med. Food. 12(1), 208-218 (2009).
74. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol. 147, S193-S201 (2006). (Pubitemid 43077277)
75. Lanas A. Role of nitric oxide in the gastrointestinal tract. Arthritis Res. Ther. 10(2), S4 (2008).
76. White WB, Schnitzer TJ, Fleming R, Duquesroix B, Beekman M. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am. J. Cardiol. 104(6), 840-845 (2009).
77. Moore A, Bjarnason I, Cryer B et al. Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm. Clin. Gastroenterol. Hepatol. 7(11), 1156-1163 (2009).
78. Cullen D, Bardhan KD, Eisner M et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment. Pharmacol. Ther. 12(2), 135-140 (1998). (Pubitemid 28059980)
79. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum. 50(8), 2433-2440 (2004). (Pubitemid 39062702)
80. Laine L, Bombardier C, Hawkey CJ et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 123(4), 1006-1012 (2002).
81. Langman MJ, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343(8905), 1075-1078 (1994).
82. Gurwitz JH, Field TS, Harrold LR et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289, 1107-1116 (2003). (Pubitemid 37430324)
83. Pilotto A, Franceschi M, Vitale D, Zaninelli A, Masotti G, Rengo F. Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms. Eur. J. Clin. Pharmacol. 62, 65-73 (2006). (Pubitemid 43106318)
84. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 284, 1247-1255 (2000).
85. Baron JA, Sandler RS, Bresalier RS et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 372(9651), 1756-1764 (2008).
86. Lanas A, Hirschowitz BI. Toxicity of NSAIDs in the stomach and duodenum. Eur. J. Gastroenterol. Hepatol. 11(4), 375-381 (1999). (Pubitemid 29199836)
87. Garcia Rodríguez LA, Hernández-Díaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 3(2), 98-101 (2001). (Pubitemid 32237035)
88. Rostom A, Dube C, Wells G et al. Prevention of NSAID induced gastroduodenal ulcers. Cochrane Database Syst. Rev. 4, 1-111 (2004).
89. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 123, 241-249 (1995).
90. Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam. Med. 28(3), 204-210 (1996). (Pubitemid 26088113)
91. Taha AS, Hudson N, Hawkey CJ et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 334(22), 1435-1439 (1996). (Pubitemid 26157439)
92. Hooper L, Brown TJ, Elliott R et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 329, 948-957 (2004).
93. Rostom A, Dubé C, Jolicoeur E, Boucher M, Joyce J. Gastro-duodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Technology report no 38. Canadian Coordinating Office for Health Technology Assessment, Ottawa, Canada (2003).
94. Pérez-Aisa MA, Del Pino D, Siles M, Lanas A. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 21(1), 65-72 (2005). (Pubitemid 40175346)
95. Graham DY, Agrawal NM, Campbell DR et al. NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch. Intern. Med. 162(2), 169-175 (2002). (Pubitemid 34098186)
96. Hawkey CJ, Karrasch JA, Szczepanski L et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) study group. N. Engl. J. Med. 338, 727-734 (1998). (Pubitemid 28115091)
97. Yeomans ND, Tulassay Z, Juhasz L et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) study group. N. Engl. J. Med. 338, 719-726 (1998). (Pubitemid 28115090)
98. Chan FK, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med. 344, 967-973 (2001). (Pubitemid 32240315)
99. Lanas A, García-Rodríguez LA, Arroyo MT et al. Investigators of the Asociación Española de Gastroenterologí a (AEG).Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol. 102(3), 507-515 (2007). (Pubitemid 46328156)
100. Lanas A, Bajador E, Serrano P et al. Nitrovasodilators, lowdose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N. Engl. J. Med. 343, 834-839 (2000).
101. García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 132(2), 498-506 (2007). (Pubitemid 46274667)
102. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292(16), 1955-1960 (2004). (Pubitemid 39411203)
103. Cunningham R, Dalea B, Undyb B, Gaunta N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J. Hosp. Infect. 54(3), 243-245 (2003). (Pubitemid 38002001)
104. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am. J. Gastroenterol. 103(9), 2308-2313 (2008).
105. Pant C, Madonia P, Minocha A. Does PPI therapy predispose to Clostridium difficile infection? Nat. Rev. Gastroenterol. Hepatol. 6(9), 555-557 (2009).
106. Chiu HF, Huang YW, Chang CC, Yang CY. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol. Drug Saf. 19(11), 1131-1136 (2010).
107. Pouwels S, Lalmohamed A, Souverein P et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos. Int. 22(3), 903-910 (2011).
108. Laine L. Proton pump inhibitors and bone fractures? Am. J. Gastroenterol. 104(2), S21-S26 (2009).
109. Geller JL, Adams JS. Proton pump inhibitor therapy and hip fracture risk. JAMA 297(13), 1429-1430 (2007).
110. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301(9), 937-944 (2009).
111. Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 363(20), 1909-1917 (2010).
112. Rostom A, Muir K, Dubé C et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin. Gastroenterol. Hepatol. 5(7), 818-828 (2007).
113. Hunt RH, Harper S, Callegari P et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol. Ther. 17(2), 201-210 (2003). (Pubitemid 36174250)
114. Mackenzie IS, Rutherford D, MacDonald TM. Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthritis Res. Ther. 10(2), S3 (2008).
115. Chan FK, Hung LC, Suen BY et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N. Engl. J. Med. 347(26), 2104-2110 (2002). (Pubitemid 36015122)
116. Lai KC, Chu KM, Hui WM et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am. J. Med. 118(11), 1271-1278 (2005).
117. Chan FK, Wong VW, Suen BY et al. Proton pump inhibitor plus a COX-2 inhibitor for the prevention of recurrent ulcer bleeding in patients with arthritis: a double blinded, randomized trial. Gastroenterology 130, A105 (2006).
118. Lanas A. Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. Aliment. Pharmacol. Ther. 20, 321-331 (2004). (Pubitemid 39062135)
119. Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG. National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ 339, b2538 (2009).
120. Lanas A, García-Tell G, Armada B, Oteo-Alvaro A. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med. 14(9), 38 (2011).
121. Sturkenboom MC, Burke TA, Tangelder MJ, Dieleman JP, Walton S, Goldstein JL. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol. Ther. 18(11-12), 1137-1147 (2003). (Pubitemid 38021600)
122. Van Soest EM, Sturkenboom MC, Dieleman JP, Verhamme KM, Siersema PD, Kuipers EJ. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol. Ther. 26(2), 265-275 (2007). (Pubitemid 46985490)
123. Abraham NS, El-Serag HB, Johnson ML et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 129(4), 1171-1178 (2005). (Pubitemid 41446857)
124. Chan FK. NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management. Drug Saf. 28(4), 287-300 (2005). (Pubitemid 40545765)
125. Huang JQ, Sridhar L, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatoryndrugs in peptic-ulcer disease: a meta-analysis. Lancet 359, 14-22 (2002). (Pubitemid 34119190)
126. Chan FK, To KF, Wu JC et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting longterm treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 359, 9-13 (2002). (Pubitemid 34119189)
127. Hawkey CJ, Tulassay Z, Szczepanski L et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet 352, 1016-1021 (1998). (Pubitemid 28438573)
128. Lai KC, Lau CS, Ip WY et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol. Ther. 17(6), 799-805 (2003). (Pubitemid 36418877)
129. Taha AS, Angerson WJ, Prasad R, McCloskey C, Blatchford O. Upper gastrointestinal bleeding and the changing use of COX-2 non-steroidal anti-inflammatory drugs and low-dose aspirin. Aliment. Pharmacol. Ther. 26(8), 1171-1178 (2007). (Pubitemid 47480957)
130. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med. 119, 624-638 (2006). (Pubitemid 44128438)
131. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol. 52(18), 1502-1517 (2008).
132. Ibáñez L, Vidal X, Vendrell L et al. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol. Ther. 23, 235-242 (2006). (Pubitemid 43382032)
133. Lanas A, García Rodríguez LA, Arroyo MT et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 55(12), 1731-1738 (2006). (Pubitemid 44893570)
134. Nakashima S, Ota S, Arai S et al. Usefulness of anti-ulcer drugs for the prevention and treatment of peptic ulcers induced by low doses of aspirin. World J. Gastroenterol. 15(6), 727-731 (2009).
135. Taha AS, McCloskey C, Prasad R et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a Phase III, randomised, double-blind, placebo-controlled trial. Lancet 374(9684), 119-125 (2009).
136. Ng FH, Wong SY, Lam KF et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 138(1), 82-88 (2010).
137. Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 346(26), 2033-2038 (2002). (Pubitemid 34680594)
138. Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med. 352(3), 238-244 (2005). (Pubitemid 40110812)
139. Lanas A. The appropriate use of proton-pump inhibitor co-therapy with non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors. Aliment Pharmacol. Ther. 21(1), 2-4, 21-24 (2005).
140. Yeomans ND, Lanas A, Talley NJ et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol. Ther. 22, 795-801 (2005). (Pubitemid 41564359)
141. Watson DJ, Harper SE, Zhao PL et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch. Intern. Med. 160, 2998-3003 (2000). (Pubitemid 32009059)
142. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritisand rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res. Ther. 7, R644-R665 (2005).
143. Hawkey C, Talley NJ, Yeomans ND. NASA1 SPACE1 Study Group Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am. J. Gastroenterol. 100(5), 1028-1036 (2005). (Pubitemid 40769038)
144. Hawkey CJ, Jones RH, Yeomans ND et al. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol. Ther. 25(7), 813-821 (2007). (Pubitemid 46434908)
145. Scheiman JM, Yeomans ND, Talley NJ et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am. J. Gastroenterol. 101(4), 701-710 (2006).
146. Laine L, Smith R, Min K et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol. Ther. 24, 751-767 (2006).
147. Lanas A, García-Rodríguez LA, Polo- Tomás M et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am. J. Gastroenterol. 104(7), 1633-1641 (2009).
148. Lanas A, Perez-Aisa MA, Feu F et al. Investigators of the Asociación Española de Gastroenterología (AEG).A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am. J. Gastroenterol. 100(8), 1685-1693 (2005). (Pubitemid 41648418)
149. Goldstein JL, Eisen GM, Lewis B et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol. Ther. 25(10), 1211-1222 (2007). (Pubitemid 46650300)
150. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP; MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 369(9560), 465-473 (2007). (Pubitemid 46217814)
151. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 376(9736), 173-179 (2010).
152. Laine L, Connors LG, Reicin A et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124, 288-292 (2003). (Pubitemid 36169245)
153. Hawkey CJ, Ell C, Simon B et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin. Gastroenterol. Hepatol. 6, 536-544 (2008).
154. Maiden L, Thjodleifsson B, Seigal A et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: cross-sectional capsule enteroscopy study. Clin. Gastroenterol. Hepatol. 5, 1040-1045 (2007).
155. Moore RA, Derry S, Henry J et al. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res. Ther. 10, R7 (2008).
156. Hawkey CJ, Jones JI, Atherton CT et al. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 52(11), 1537-1542 (2003). (Pubitemid 37363434)
157. Niwa Y, Nakamura M, Ohmiya N et al. Efficacy of rebamipide for diclofenac induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J. Gastroenterol. 43(4), 270-276 (2008). (Pubitemid 351650037)
158. Sivalingam N, Hanumantharaya R, Faith M et al. Curcumin reduces indomethacin- induced damage in the rat small intestine. J. Appl. Toxicol. 27(6), 551-560 (2007). (Pubitemid 350113421)
159. Hayllar J, Smith T, Macpherson A et al. Nonsteroidal antiinflammatory drug induced small intestinal inflammation and blood loss. Effects of sulfasalazine and other disease-modifying antirheumatic drugs. Arthritis Rheum. 37, 1146-1150 (1994). (Pubitemid 24313313)
160. Scarpignato C. NSAID-induced intestinal damage: are luminal bacteria the therapeutic target? Gut 57, 145-148 (2008). (Pubitemid 351158035)
161. Lanas A, Scarpignato C. Microbial flora in NSAID induced intestinal damage: a role for antibiotics? Digestion 73(1), 36-50 (2006).
162. Bjarnason I, Hayllar J, Smethurst P et al. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut 33(9), 1204-1208 (1992).
163. Huntjens DR, Danhof M, Della Pasqua OE. Pharmacokineticpharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford) 44, 846-859 (2005). (Pubitemid 41511177)
164. Antman EM, Bennett JS, Daugherty A et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115, 1634-1642 (2007). (Pubitemid 46648649)
165. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345, 1809-1817 (2001).
166. Renda G, Tacconelli S, Capone ML et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin. Pharmacol. Ther. 80, 264-274 (2006). (Pubitemid 44313900)
167. Anzellotti P, Capone ML, Jeyam A et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis. Rheum. 63, 850-859 (2011).
168. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71-86 (2002).